RNAC
Cartesian Therapeutics·NASDAQ
--
--(--)
--
--(--)
4.79 / 10
Netural
Liquidity flow is robust at 7.56/10, yet the analyst consensus is overwhelmingly bullish with a Strong Buy rating from one analyst. This divergence suggests potential short-term buying pressure but long-term uncertainty.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
100%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-01-09
InstitutionNeedham
Times predicted4
Historical Win Rate25.0%
What is the analyst consensus for RNAC?
- RNAC holds a Bearish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 4.79/10 (Netural).
